Array BioPharma, Inc. (NASDAQ:ARRY)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases.

Recs

0
Player Avatar tking123 (54.17) Submitted: 4/29/2011 3:10:55 PM : Outperform Start Price: $3.10 ARRY Score: +14.68

cancer drug could be approved

Featured Broker Partners


Advertisement